CADL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CADL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.
Candel Therapeutics's current Total Payout Ratio is 0.01.
The historical data trend for Candel Therapeutics's Total Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Candel Therapeutics Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Total Payout Ratio | - | - | 1.98 | - | - |
Candel Therapeutics Quarterly Data | ||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Total Payout Ratio | Get a 7-Day Free Trial | - | - | - | - | 0.02 |
For the Biotechnology subindustry, Candel Therapeutics's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Candel Therapeutics's Total Payout Ratio distribution charts can be found below:
* The bar in red indicates where Candel Therapeutics's Total Payout Ratio falls into.
Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.
Candel Therapeutics's Total Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Total Payout Ratio | = | - (Repurchase of Stock | + | Issuance of Stock | + | Cash Flow for Dividends) | / | Net Income |
= | - (0 | + | 0 | + | 0) | / | -37.939 | |
= | 0.00 |
Candel Therapeutics's Total Payout Ratio for the quarter that ended in Mar. 2024 is calculated as
Total Payout Ratio | = | - (Repurchase of Stock | + | Issuance of Stock | + | Cash Flow for Dividends) | / | Net Income |
= | - (0 | + | 0.186 | + | 0) | / | -8.221 | |
= | 0.02 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Candel Therapeutics's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Nicoletta Loggia | director | CANDEL THERAPEUTICS, INC., 117 KENDRICK ST., SUITE 450, NEEDHAM MA 02494 |
Jason Amello | officer: Chief Financial Officer | 500 KENDALL STREET, CAMBRIDGE MA 01824 |
Paul Peter Tak | director, officer: President & CEO | CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494 |
Christopher Martell | director | CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494 |
Seshu Tyagarajan | officer: See Remarks | CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494 |
Joseph C Papa | director | C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807 |
Francesca Barone | officer: Chief Scientific Officer | CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494 |
William Garrett Nichols | officer: Chief Medical Officer | C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494 |
Gary J. Nabel | director | C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065 |
Renee Gaeta | director | C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958 |
Paul B Manning | director | 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902 |
Diem Nguyen | director | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
Nathan Caffo | officer: Chief Business Officer | C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010 |
John J Canepa | officer: Chief Financial Officer | 241 MATTINSON DRIVE, CONCORD MA 01742 |
Susan B. Stewart | officer: Chief Regulatory Officer | C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
From GuruFocus
By sperokesalga sperokesalga • 05-02-2023
By Stock market mentor Stock market mentor • 02-01-2023
By PurpleRose PurpleRose • 08-01-2022
By Marketwired • 09-26-2023
By PurpleRose PurpleRose • 08-05-2022
By Value_Insider Value_Insider • 12-06-2022
By Marketwired • 11-04-2023
By GuruFocusNews GuruFocusNews • 07-07-2022
By Value_Insider Value_Insider • 11-10-2022
By sperokesalga sperokesalga • 06-13-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.